Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
154
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endoscopic detection of signet ring cell carcinoma in CDH1 carriers: a 15-year single-centre experience.

Familial cancer·2026
Same author

Educator as Coach: Teaching Clinical Performance Using Wearable Data.

AEM education and training·2026
Same author

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Future oncology (London, England)·2026
Same author

Multicomponent Behavior Change Technique Intervention for Caregivers of People With Alzheimer Disease and Related Dementias: Protocol for a Single-Arm, Personalized Behavioral Trial to Disrupt Sedentary Time.

JMIR research protocols·2026
Same author

Defining Ultrasound-Guided Nerve Block Competency for Emergency Medicine: A Delphi-Method Consensus Statement.

AEM education and training·2026
Same author

Donor-derived airway air-liquid interface model for high-throughput screening of antiviral combinations with concurrent analysis of antiviral efficacy and epithelial toxicity using ciliR.

ERJ open research·2026
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

646

Preoperative Chemoradiotherapy for Resectable Gastric Cancer.

Trevor Leong1, B Mark Smithers1, Michael Michael1

  • 1From the Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne (T.L., M.M., W.K.M.), the School of Public Health, Monash University (J.Z.), the Department of Medical Oncology, Alfred Health (J.Z.), Central Clinical School, Alfred Centre (A.B.), and Monash Medical Centre (A.S.), Melbourne, VIC, Princess Alexandra Hospital, University of Queensland, Brisbane (B.M.S.), and Cancer Care Services, Sunshine Coast University Hospital, Birtinya, QLD (D.W.), National Health and Medical Research Council Clinical Trials Centre, University of Sydney (V.G., R.L.O., J.S.), and Chris O'Brien Lifehouse (D.M.), Sydney, and the Trans-Tasman Radiation Oncology Group, University of Newcastle, Newcastle, NSW (A.M.) - all in Australia; the Department of Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium (K.H.); Princess Margaret Hospital (R.W.) and Mount Sinai Hospital (C.S.), Toronto, the Canadian Cancer Trials Group, Queen's University, Kingston, ON (C.O.), Nova Scotia Health Central Zone, Halifax (G.D.), and Centre Hospitalier de l'Université de Montréal, Montreal (M.L.) - all in Canada; the Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand (M.F.); University Cancer Center Leipzig and Comprehensive Cancer Center Central Germany Leipzig-Jena, University Medicine Leipzig, Leipzig, Germany (F.L.); and Sainte Catherine Institut du Cancer Avignon-Provence, Avignon, France (L.M.).

The New England Journal of Medicine
|September 16, 2024
PubMed
Summary
This summary is machine-generated.

Adding preoperative chemoradiotherapy to perioperative chemotherapy did not improve overall survival for gastric cancer patients. Standard perioperative chemotherapy alone remains the comparable treatment for resectable gastric and gastroesophageal junction adenocarcinoma.

More Related Videos

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
10:31

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma

Published on: August 9, 2016

12.7K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K

Related Experiment Videos

Last Updated: Jun 13, 2025

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
03:32

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

646
Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
10:31

Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma

Published on: August 9, 2016

12.7K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K

Area of Science:

  • Oncology
  • Gastrointestinal Surgery
  • Radiation Oncology

Background:

  • The standard treatment for resectable gastric cancer in Western countries is perioperative chemotherapy.
  • Preoperative chemoradiotherapy is an alternative, but comparative data are limited.

Purpose of the Study:

  • To compare the efficacy of preoperative chemoradiotherapy plus perioperative chemotherapy versus perioperative chemotherapy alone for resectable gastric and gastroesophageal junction adenocarcinoma.

Main Methods:

  • An international, phase 3 randomized trial involving 574 patients.
  • Patients received either preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone.
  • Chemotherapy regimens included epirubicin, cisplatin, and fluorouracil or fluorouracil, leucovorin, oxaliplatin, and docetaxel. Preoperative chemoradiotherapy involved 45 Gy radiation in 25 fractions with fluorouracil infusion.

Main Results:

  • A higher pathological complete response rate (17% vs. 8%) and greater tumor downstaging were observed in the preoperative chemoradiotherapy group.
  • No significant differences in overall survival (median 46 vs. 49 months) or progression-free survival (median 31 vs. 32 months) were found between the groups.
  • Treatment-related toxic effects were similar in both groups.

Conclusions:

  • The addition of preoperative chemoradiotherapy to perioperative chemotherapy does not enhance overall survival for patients with resectable gastric and gastroesophageal junction adenocarcinoma.
  • Perioperative chemotherapy alone demonstrates comparable survival outcomes to the combined approach.